Gut microbiota: a new piece in understanding hepatocarcinogenesis.
Gut microbiota: a new piece in understanding hepatocarcinogenesis.
复制标题
DOI：
10.1016/j.canlet.2020.01.002
复制
发表时间：
2020-01
期刊：
影响因子：
9.7
通讯作者：
An Zhou;Li Tang;Shuo Zeng;Yuanyuan Lei;Shiming Yang;Bo Tang
中科院分区：
文献类型：
--
作者：
An Zhou;Li Tang;Shuo Zeng;Yuanyuan Lei;Shiming Yang;Bo Tang
肠道微生物群与宿主形成共生关系，并在生活的许多关键方面对身体有益。然而，免疫系统缺陷、肠道微生物群的改变和环境变化会破坏这种共生关系，并可能导致疾病，包括癌症。由于肠道和肝脏在解剖和功能上的联系，越来越多的研究表明肠道微生物群在肝细胞癌（HCC）的发生中起着重要作用。在这篇文章中，我们回顾了现有的证据，并分析了肠道微生物群的一些潜在机制，包括细菌生态失调，脂多糖（LPS）和遗传毒素，在HCC的进展和促进。此外，我们还讨论了益生菌、化疗调节、免疫治疗、靶向药物和粪便微生物群移植（FMT）在靶向肠道微生物群方面的可能治疗应用。
The gut microbiota forms a symbiotic relationship with the host and benefits the body in many critical aspects of life. However, immune system defects, alterations in the gut microbiota and environmental changes can destroy this symbiotic relationship and may lead to diseases, including cancer. Due to the anatomic and functional connection of the gut and liver, increasing studies show the important role of the gut microbiota in the carcinogenesis of hepatocellular carcinoma (HCC). In this manuscript, we review the available evidence and analyze some potential mechanisms of the gut microbiota, including bacterial dysbiosis, lipopolysaccharide (LPS), and genotoxins, in the progression and promotion of HCC. Furthermore, we discuss the possible therapeutic applications of probiotics, chemotherapy modulation, immunotherapy, targeted drugs and fecal microbiota transplantation (FMT) in targeting the gut microbiota.